On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.